| Business Summary | | Cellegy
Pharmaceuticals,
Inc.
is
a
specialty
biopharmaceutical
company
engaged
in
the
development
of
prescription
drugs
and
skin
care
products.
The
Company's
prescription
products
are
directed
toward
the
treatment
of
gastrointestinal
disorders,
sexual
dysfunction
of
both
men
and
women
and
conditions
affecting
women's
health.
Cellegy's
most
advanced
prescription
product
candidates
include
Anogesic
(nitroglycerin
ointment)
for
the
treatment
of
anal
fissures
and
hemorrhoids,
and
Tostrex
(testosterone
gel)
for
the
treatment
of
male
hypogonadism,
a
condition
that
frequently
can
result
in
lethargy
and
reduced
libido
in
men. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Cellegy
is
a
biopharmaceutical
company
engaged
in
the
development
of
prescription
drugs
and
cosmeceuticals
to
address
a
variety
of
diseases
and
conditions
utilizing
its
patented
transdermal
and
topical
delivery
technologies.
For
the
six
months
ended
6/30/01,
revenues
decreased
86%
to
$94
thousand.
Net
loss
increased
72%
to
$7.9
million.
Revenues
reflect
the
absence
of
product
sales
to
Gryphon
Development.
Higher
loss
was
partially
offset
by
higher
interest
income. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| K. Michael Forrest, 57 Chairman,
Pres, CEO | $303K | -- | Daniel Azarnoff, M.D., 74 Sr.
VP- Clinical and Regulatory Affairs | 126K | -- | A. Richard Juelis, 51 VP
of Fin. and CFO | 178K | $230K | John Chandler VP
of Bus. Devel. | 181K | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|